Identification of a novel extracellular inhibitor of FGF2/FGFR signaling axis by combined virtual screening and NMR spectroscopy approach.


Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
07 2023
Historique:
received: 10 03 2023
accepted: 03 04 2023
medline: 29 5 2023
pubmed: 22 4 2023
entrez: 21 04 2023
Statut: ppublish

Résumé

The aberrant activation of the fibroblast growth factor 2 (FGF2)/fibroblast growth factor receptor (FGFR) signalling pathway drives severe pathologies, including cancer development and angiogenesis-driven pathologies. The perturbation of the FGF2/FGFR axis via extracellular allosteric small inhibitors is a promising strategy for developing FGFR inhibitors with improved safety and efficacy for cancer treatment. We have previously investigated the role of new extracellular inhibitors, such as rosmarinic acid (RA), which bind the FGFR-D2 domain and directly compete with FGF2 for the same binding site, enabling the disruption of the functional FGF2/FGFR interaction. To select ligands for the previously identified FGF2/FGFR RA binding site, NMR data-driven virtual screening has been performed on an in-house library of non-commercial small molecules and metabolites. A novel drug-like compound, a resorcinol derivative named RBA4 has been identified. NMR interaction studies demonstrate that RBA4 binds the FGF2/FGFR complex, in agreement with docking prediction. Residue-level NMR perturbations analysis highlights that the mode of action of RBA4 is similar to RA in terms of its ability to target the FGF2/FGFR-D2 complex, inducing perturbations on both proteins and triggering complex dissociation. Biological assays proved that RBA4 inhibited FGF2 proliferative activity at a level comparable to the previously reported natural product, RA. Identification of RBA4 chemical groups involved in direct interactions represents a starting point for further optimization of drug-like extracellular inhibitors with improved activity.

Identifiants

pubmed: 37084585
pii: S0045-2068(23)00189-X
doi: 10.1016/j.bioorg.2023.106529
pii:
doi:

Substances chimiques

Fibroblast Growth Factor 2 103107-01-3
Receptors, Fibroblast Growth Factor 0
Resorcinols 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106529

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper: [Collina Simona reports financial support was provided by University of Pavia.].

Auteurs

Katiuscia Pagano (K)

Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" (SCITEC), Consiglio Nazionale delle Ricerche, via Corti 12, 20133 Milano, Italy.

Roberta Listro (R)

University of Pavia, Department of Drug Sciences, Via Taramelli 12, 27100 Pavia, Italy.

Pasquale Linciano (P)

University of Pavia, Department of Drug Sciences, Via Taramelli 12, 27100 Pavia, Italy.

Daniela Rossi (D)

University of Pavia, Department of Drug Sciences, Via Taramelli 12, 27100 Pavia, Italy. Electronic address: daniela.rossi@unipv.it.

Elisa Longhi (E)

Laboratory of Tumor Microenvironment, Department of Oncology, Istituto di Ricerche Farmacologiche, Mario Negri IRCCS, 24126 Bergamo, Italy.

Giulia Taraboletti (G)

Laboratory of Tumor Microenvironment, Department of Oncology, Istituto di Ricerche Farmacologiche, Mario Negri IRCCS, 24126 Bergamo, Italy.

Henriette Molinari (H)

Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" (SCITEC), Consiglio Nazionale delle Ricerche, via Corti 12, 20133 Milano, Italy.

Simona Collina (S)

University of Pavia, Department of Drug Sciences, Via Taramelli 12, 27100 Pavia, Italy.

Laura Ragona (L)

Istituto di Scienze e Tecnologie Chimiche "Giulio Natta" (SCITEC), Consiglio Nazionale delle Ricerche, via Corti 12, 20133 Milano, Italy. Electronic address: laura.ragona@scitec.cnr.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH